Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

2008217 citationsJournal Article

Authors

At 12 months, immediate zoledronic acid therapy prevented bone loss in postmenopausal women who were receiving adjuvant letrozole.

Good health and well-being

Published in: Cancer

Volume 112, Issue 5, pp. 1001-1010

Field-Weighted Citation Impact: 15.25